Logo image of NKGN

NKGEN BIOTECH INC (NKGN) Stock Fundamental Analysis

NASDAQ:NKGN - Nasdaq - US65488A1016 - Common Stock - Currency: USD

0.8418  +0.46 (+121.64%)

After market: 0.69 -0.15 (-18.03%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NKGN. NKGN was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of NKGN have multiple concerns. NKGN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NKGN has reported negative net income.
In the past year NKGN has reported a negative cash flow from operations.
NKGN Yearly Net Income VS EBIT VS OCF VS FCFNKGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of NKGN (-564.01%) is worse than 97.88% of its industry peers.
Industry RankSector Rank
ROA -564.01%
ROE N/A
ROIC N/A
ROA(3y)-167.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NKGN Yearly ROA, ROE, ROICNKGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -200 -400

1.3 Margins

NKGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NKGN Yearly Profit, Operating, Gross MarginsNKGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, NKGN has more shares outstanding
Compared to 1 year ago, NKGN has a worse debt to assets ratio.
NKGN Yearly Shares OutstandingNKGN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
NKGN Yearly Total Debt VS Total AssetsNKGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -26.80, we must say that NKGN is in the distress zone and has some risk of bankruptcy.
NKGN's Altman-Z score of -26.80 is on the low side compared to the rest of the industry. NKGN is outperformed by 90.27% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.8
ROIC/WACCN/A
WACCN/A
NKGN Yearly LT Debt VS Equity VS FCFNKGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.02 indicates that NKGN may have some problems paying its short term obligations.
With a Current ratio value of 0.02, NKGN is not doing good in the industry: 99.82% of the companies in the same industry are doing better.
NKGN has a Quick Ratio of 0.02. This is a bad value and indicates that NKGN is not financially healthy enough and could expect problems in meeting its short term obligations.
NKGN has a Quick ratio of 0.02. This is amonst the worse of the industry: NKGN underperforms 99.82% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
NKGN Yearly Current Assets VS Current LiabilitesNKGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for NKGN have decreased strongly by -50.83% in the last year.
EPS 1Y (TTM)-50.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NKGN Yearly Revenue VS EstimatesNKGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023
NKGN Yearly EPS VS EstimatesNKGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NKGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKGN Price Earnings VS Forward Price EarningsNKGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKGN Per share dataNKGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NKGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NKGEN BIOTECH INC

NASDAQ:NKGN (2/12/2025, 8:00:01 PM)

After market: 0.69 -0.15 (-18.03%)

0.8418

+0.46 (+121.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12
Earnings (Next)04-14 2025-04-14
Inst Owners10.03%
Inst Owner Change-65.04%
Ins Owners0.58%
Ins Owner Change-6.49%
Market Cap30.32M
AnalystsN/A
Price TargetN/A
Short Float %2.66%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.71
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0
BVpS-1.94
TBVpS-1.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -564.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-167.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -26.8
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.1%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-117.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4031.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4022.8%
OCF growth 3YN/A
OCF growth 5YN/A